Pages
- Events
- News & Events
- News Center
- Press Releases
- About Us
- Contact Us
- Home
- Our Science
- Privacy
- Sitemap
- Terms of Use
- Depression
- Ischemia
- Neuropathic Pain
- Product Development Team
Posts by category
- Category: Events
- Category: Investor Relations
- Category: Press Releases
- NeurOp Receives FDA Orphan Drug Designation for NP10679 for Treatment of Subarachnoid Hemorrhage
- NeurOp Announces Positive Topline Data from Phase 1 Studies for Lead Candidate NP10679 for CNS Disorders
- NeurOp Initiates Phase 1 Clinical Trial of NMDA Receptor Inhibitor NP10679
- NIH Awards NeurOp $3.5 Million to Support Phase 1 Clinical Trial of NMDA Inhibitor NP10679
- NeurOp’s Lee Latimer Elected to ACS 2016 Board of Directors
- NeurOp Announces Strategic Collaboration with Johnson & Johnson Innovation to Study Role of NMDA Receptors
- NeurOp Receives Milestone Payment as Bristol-Myers Squibb Nominates NMDA Receptor Compound as Drug Development Candidate
- NeurOp Awarded NIH Grant for Alzheimer’s Disease Drug Research
- Lee H. Latimer Joins NeurOp to Manage Its Chemistry Operations
- NeurOp Selects NP10679 as Development Candidate for SAH
- NeurOp Receives Third Year of NIH Funding for Ischemia Research
- NeurOp Receives Second Half of NIH Grant for Meeting Schizophrenia Research Milestones
- NeurOp and Emory Scientists Target Cognitive and Mental Health Disorders